Propanc Receives Additional $525,000 from Institutional Investor; Initiates Animal Safety Toxicology Studies for PRP

MELBOURNE, Australia, Jan. 13, 2016, PPCH, /PRNewswire/ Propanc Health Group Corporation (OTCQB: PPCH) ( Propanc or the Company ), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, today announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. To date, the Company has received approximately $2.4 Million from the Institutional Investor since the Securities Purchase Agreement, Debenture and Warrant (the Financing Documents ) were executed by both parties on October 28th. The balance of the investment amount of approximately $1.6 Million shall be paid (totaling $4 Million) in the future, pending the achievement of certain equity conditions set forth in the Financing Documents, as described in the Company s recent filings. The aggregate deal size provides sufficient capital


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: